A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

NCT03914794 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
NMIBC
Non-Muscle Invasive Bladder Cancer
Urothelial Carcinoma Recurrent

Interventions

DRUG: Pemigatinib

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]